Politecnico di Torino has been awarded the prestigious ERC Advanced Grant
TURIN, Italy, June 17, 2025 (GLOBE NEWSWIRE) — Politecnico di Torino's research project 'IntelliSwarm' has been awarded the prestigious ERC Advanced Grant, an initiative of the European Research Council aimed at supporting the practical application and exploitation of the results of frontier research projects. This represents a significant opportunity for researchers from across Europe who, in order to participate in the selection process, must be recognised as leaders in their field of research, with a proven track record of excellence that ensures the delivery of original results and a positive impact on the future of society. A total of 281 projects received funding across Europe, including 25 in Italy.
The scientific coordinator of the project is Enrico Magli, Professor at the Department of Electronics and Telecommunications-DET, who will receive €3 million to invest in research over the next five years. By assembling a team of experts and investing in state-of-the-art computing infrastructure, the project aims to increase the quality, availability and timeliness of images processed on board satellites, thereby optimising the use of inter-satellite and satellite-to-ground communication links.
In a world that increasingly needs accurate data to interpret and predict phenomena and events of collective interest – with particular attention to environmental disasters that affect our regions with growing frequency, such as floods and wildfires – the studies conducted by Professor Magli have the ambition of collecting images of the Earth's surface with significantly higher spatial and spectral resolution and 3D reconstruction capabilities. This is achieved through the use of advanced artificial intelligence techniques and processing carried out by a swarm of satellites. The swarm enables cooperation between different satellites, providing a distributed acquisition and calculation paradigm. This has the advantage of overcoming the limitations of a single large satellite and ensuring robustness, as the failure of one satellite does not compromise the functionality of the system as a whole.
Beyond space applications: The methods developed within the project will also be relevant for other types of 'embedded' systems, thereby extending the impact of the research to different fields of investigation, such as sensor networks and the Internet of Things.
'Earth observation from space is a rapidly expanding field with a variety of applications in sustainability, environmental disaster management, and spatial analysis – explains Professor Magli – the 'IntelliSwarm' aims to develop highly sophisticated instruments and modes of observation, distributing their complexity across a large number of small satellites, overcoming the limitations of optics with AI, and running advanced AI models directly on board the satellites. I find the project extremely stimulating because of the scientific problems it will lead us to address, which will also have implications for the use of AI in systems based on low-power computing nodes. Looking ahead, a possible continuation of the project involves training models directly on board the satellites, enabling them to learn continuously from all observed images.'
' This recognition reflects the growing importance of excellence in research within Politecnico,' says Rector Stefano Corgnati. ' Being internationally competitive requires full synergy between experiential learning and increasingly essential research and innovation activities. The opportunities offered by the ERC Advanced Grant will also strengthen our appeal within the international research landscape, laying the groundwork to attract top young talent and enabling them to engage with cutting-edge projects. '
For further information, please visit the official ERC website: https://erc.europa.eu/news-events/news/erc-2024-advanced-grants-results
For more information:
Press Office LaPresse – [email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e98ad666-566c-4ea7-87b9-65ea71c009dd
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Google tweaks Google Play conditions following EU pressure
PARIS (Reuters) -Alphabet unit Google said on Tuesday it will make it easier for app developers to steer customers to channels other than Google after the European Union competition watchdog charged it with breaching EU regulations. In March, Google was hit with two charges of breaching the EU's landmark Digital Markets Act (DMA), which aims to rein in the power of Big Tech. Google has been in the European Commission's crosshairs since early 2024 over whether it restricts app developers from informing users about offers outside its app store Google Play and whether it favours its vertical search services such as Google Flights. Regulators have said Alphabet technically prevents app developers from freely steering consumers to other channels for better offers. They said a service fee charged by the company for facilitating the initial acquisition of a new customer by an app developer via Google Play goes beyond what is justified. In a blog post, Google said that following discussions with the European Commission, developers, and other experts, Google is updating certain terms. "While we still have concerns that these changes could expose Android users to harmful content and make the app experience worse, we're updating our External Offers Program for the EU with revised fees and more options for Android developers, following DMA discussions with the European Commission," EMEA Senior Competition Counsel Clare Kelly said. The company, which has been fined more than 8 billion euros ($9.3 billion) by the EU for various antitrust violations, risks fines of up to 10% of its global annual sales if found guilty of breaching the DMA. ($1 = 0.8580 euros)
Wall Street Journal
3 hours ago
- Wall Street Journal
Google Offers to Tweak Play Store Terms to Stave Off EU Fine
Alphabet's Google has offered to change terms and conditions for developers using its Play Store in a bid to stave off a potential fine under European Union tech rules. Google said in a blog post on Tuesday that it would alter fees it charges developers for app downloads and make it easier to lead users to deals and offers outside of its own app store.
Yahoo
3 hours ago
- Yahoo
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA improves MRD-negativity rates; 78% among responders 100% CR/CRh in FLT3 wildtype AML, representing 70% of AML population 100% CR/CRh and MRD-negativity rates in TP53, RAS and FLT3-ITD mutated AML Broad spectrum activity and excellent safety profile continue at 120 mg dose to date SAN DIEGO and TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ('Aptose' or the 'Company') (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today provided a data update from the Phase 1/2 TUSCANY trial in newly diagnosed AML. The trial was initiated in December 2024, and the growing body of positive data includes the recently completed third cohort of 120 mg TUS in the TUS+VEN+AZA triplet therapy. Data to date from ten (10) patients across all three cohorts, 40 mg, 80 mg or 120 mg TUS dose in TUS+VEN+AZA, support the use of TUS with standard of care treatment across all AML populations, including those carrying mutations that are the most difficult to treat and those with mutated and unmutated (wildtype) FLT3 genes. The TUS+VEN+AZA triplet is being developed as a safe and well-tolerated mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. At the 120 mg TUS dose level in combination with VEN+AZA, as with the prior reported 40 mg and 80 mg TUS dose cohorts, no significant safety concerns or dose limiting toxicities (DLTs) have been observed in the TUSCANY trial, including no prolonged myelosuppression in Cycle 1 of subjects in remission, no reports of drug-related QTc prolongation or differentiation syndrome (DS), and no treatment-related deaths. Nine out of ten dosed patients remain on study across all dose cohorts and enrollment is being advanced to the 160 mg TUS dose level following the Cohort Safety Review Committee (CSRC) meeting. 'We already have data from three different TUS dose levels in the TUSCANY trial, and the data continue to strengthen at higher doses of TUS and over time. We are building a strong case for TUS+VEN+AZA as a triplet frontline therapy of choice to address a broad AML population, including subgroups with the most adverse of mutations,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. Data highlights: Comparison of CR/CRh1 Response rates2-5: VEN+AZA2 TUS+VEN+AZA All subjects 65% 90% (9/10) NPM1-mutant 67% 100% (2/2) FLT3-ITD 61% 100% (2/2) TP53-mutant 52% 100% (2/2) Comparison of MRD-negativity6 rates among All Subjects and among CR/CRh Responders3: VEN+AZA2,3 TUS+VEN+AZA Among All Subjects 23.4% 70% (7/10) Among CR/CRh Responders 40.9% 78% (7/9) Comparison of MRD-negativity rates among more difficult-to-treat Patient Subpopulations defined as Lower Benefit (TP53-mutated) and Intermediate Benefit (FLT3-ITD or RAS-mutated) relative to VEN+AZA5: VEN+AZA3,5 TUS+VEN+AZA Intermediate Benefit 27.9% 100% (3/3) Lower Benefit 14.5% 100% (2/2) TUS+VEN+AZA - CR/CRh and MRD-negativity rates among Subjects with Adverse Mutations: TP53, FLT3-ITD, RAS mutations: Achieved CR/CRh and MRD-negativity 100% (5/5) 'As illustrated in the data highlights, the addition of TUS to VEN+AZA appears to boost response rates and MRD-negativity while maintaining favorable safety and tolerability,' said Rafael Bejar, M.D., Ph.D., Chief Medical Officer of Aptose, 'and the 100% CR/CRh and 100% MRD-negativity rates among the five biallelic TP53-mutant, FLT3-ITD, and RAS-mutant AML cases are exciting to see, as this can correlate with longer overall survival. We have observed a trend towards achieving CRs more quickly at the higher dose levels, so we are keen to see the activity as we advance into the 160 mg TUS dose cohort.' Key messages: Addition of TUS to VEN+AZA demonstrates excellent CR/CRh rates 100% CR/CRh among all subjects treated at 80 mg and 120 mg TUS dose levels Appear to be achieving CR earlier with 120 mg TUS than with 40 mg or 80 mg Addition of TUS to VEN+AZA demonstrates excellent MRD-negativity rates MRD-negativity in 7 of 9 (78%) already achieved in patients who responded to therapy Expect patient survival to be extended with continued long-term treatment Excellent safety and well tolerated with no dose-limiting toxicities (No DLT) at completed dose levels Broad-spectrum activity including patients with adverse TP53, RAS and FLT3-ITD mutations No loss of MRD-negativity observed to date, including in one patient with over 7 months of follow up MRD-negativity and remissions continue to mature over time on therapy No relapses reported to date and no treatment related deaths The only non-responder was a patient at the initial TUS dose level (40 mg) that did not achieve TUS exposures previously associated with response Additional data are included in the new Aptose corporate presentation here. TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. The TUSCANY triplet Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on (here). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences PietropaoloCorporate Communications & Investor Relations201-923-2049spietropaolo@ 1 Complete Response / Complete Response with Partial Hematological Recovery2 DiNardo et al. New England Journal of Medicine, August 2020; Volume 383(7):617-629.3 Pratz et al. Journal of Clinical Oncology, December 2021; Volume 40 (8):855-865.4 Othman et. al. Blood Neoplasia; September 2024; Volume 1 (3):1-11.5 Döhner et. al. Blood. 2024 November 21;144(21):2211-2222.6 MRD-negative indicates that the amount of Measurable Residual Disease, as assessed by central flow cytometry, is such that the proportion of leukemic cells in a bone marrow sample falls below <0.1%Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
